FY2029 EPS Forecast for Medicus Pharma Lowered by Analyst

Medicus Pharma Ltd (NASDAQ:MDCX) – Brookline Capital Markets lowered their FY2029 EPS estimates for Medicus Pharma in a research report issued on Friday, August 14th. Brookline Capital Markets analyst K. Raja now anticipates that the company will earn $0.65 per share for the year, down from their previous forecast of $0.73. The consensus estimate for Medicus Pharma’s current full-year earnings is ($0.51) per share. Brookline Capital Markets also issued estimates for Medicus Pharma’s FY2030 earnings at $1.22 EPS.

Several other research firms also recently commented on MDCX. D. Boral Capital reiterated a “buy” rating and set a $9.00 price objective on shares of Medicus Pharma in a research note on Monday, April 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of Medicus Pharma in a research report on Wednesday, July 8th. Roth Capital started coverage on Medicus Pharma in a research report on Tuesday, April 21st. They set a “buy” rating for the company. Finally, Alliance Global Partners reaffirmed a “buy” rating on shares of Medicus Pharma in a research report on Monday. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $9.00.

Medicus Pharma Trading Down 7.2%

NASDAQ:MDCX opened at $0.26 on Monday. Medicus Pharma has a twelve month low of $0.25 and a twelve month high of $3.05. The company has a market cap of $16.43 million, a PE ratio of -0.11 and a beta of 0.12. The company’s 50 day moving average is $0.37 and its two-hundred day moving average is $0.53.

Medicus Pharma (NASDAQ:MDCX) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.08).

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MDCX. Private Advisor Group LLC boosted its holdings in Medicus Pharma by 3.8% in the third quarter. Private Advisor Group LLC now owns 151,500 shares of the company’s stock valued at $351,000 after purchasing an additional 5,500 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Medicus Pharma during the 2nd quarter valued at about $41,000. HRT Financial LP purchased a new position in shares of Medicus Pharma during the 4th quarter valued at about $42,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Medicus Pharma in the 3rd quarter valued at about $59,000. Finally, Armistice Capital LLC acquired a new position in shares of Medicus Pharma in the 4th quarter valued at about $2,771,000.

About Medicus Pharma

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.